AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II


Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Still some way to go...
Upside 225%
Price (€) 3.53
Market Cap (€M) 128
Perf. 1W: 6.98%
Perf. 1M: -2.22%
Perf. 3M: -24.5%
Perf Ytd: 6.98%
10 day relative perf. to stoxx600: 4.22%
20 day relative perf. to stoxx600: 5.99%
EPS change27/03/2023

No real news in the FY22 results.

Change in EPS2023 : € -0.23 vs -0.33ns
2024 : € 0.49 vs 0.41+20.8%

We have updated our model after the release of the FY22 results. The latter were not meaningful (as usual) since the investment case is based on future product launches (hopefully as of FY24). Concerning our short-term earnings forecasts, they have been fine-tuned to factor in a slightly-higher contribution to revenues from the BARDA agreement signed last June. This is not a game changer in the short-term, but will still provide the group with an extra financing source in the current year and next.